Rate My Professor Remi Adelaiye-Ogala

Her research program investigates mechanistic determinants of therapeutic resistance in genitourinary cancers, with emphasis on molecular regulation of signaling pathways in prostate and renal cancers through epigenetics, genomics and proteomics, transcriptomics, preclinical models, and translational strategies to overcome drug resistance. Ongoing projects include targeting drivers of androgen receptor cistrome reprogramming in advanced aggressive prostate cancer, posttranslational modulations and dynamics of pro-oncogenic glucocorticoid receptor activity in enzalutamide-resistant prostate cancers, and development of patient-derived xenograft and organoid models from underrepresented populations. She received a five-year, $3 million NIH R01 grant from the National Cancer Institute as a MERIT R37 award titled “Posttranslational Modifications of Glucocorticoid Receptor Associated With Drug-Resistance in Prostate Cancer” and the Prostate Cancer Foundation Young Investigator award. Key publications include “MECOM Function is Critical for AR-Driven Treatment-Resistant Prostate Cancer” (Cancer Research, 2026), “Coactivator Networks Orchestrating Noncanonical AR Programs in Enzalutamide-Resistant CRPC” (Frontiers in Oncology, 2026), “Small-molecule disruption of androgen receptor-dependent chromatin clusters” (Proceedings of the National Academy of Sciences, 2024), “Glucocorticoid receptor (GR) activation is associated with increased cAMP/PKA signaling in castrate-resistant prostate cancer” (Molecular Cancer Therapeutics, 2023), and “Targeting the PI3K/AKT Pathway Overcomes Enzalutamide Resistance by Inhibiting Induction of the Glucocorticoid Receptor” (Molecular Cancer Therapeutics, 2020).